Protalix BioTherapeutics

Company Overview

Snapshot

Founded in January 1994, Protalix BioTherapeutics operates with 51–200 employees. The company has raised $159.9M across 11 funding rounds from 5 investors. In February 2021, the company completed a public offering, raising approximately $40 million.

Business overview

Protalix BioTherapeutics is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins. The company utilizes its proprietary ProCellEx plant-cell-based protein expression system to create potentially clinically superior versions of therapeutic proteins for established pharmaceutical markets. Its product pipeline includes treatments for genetic disorders and inflammatory diseases, serving the broader Health Tech & Life Sciences sector, particularly within pharmaceuticals and drug development.

Strategic signal

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes. This move signals a strengthening financial position and a commitment to reducing debt, which could enhance investor confidence and provide greater financial flexibility for future research and development initiatives within the biopharmaceutical industry.

Company Intelligence Q&A

What is Protalix BioTherapeutics' core technology?

Protalix BioTherapeutics develops, produces, and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant-cell-based protein expression system.

When did Protalix BioTherapeutics complete its most recent public offering?

In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million.

Which product of Protalix BioTherapeutics received FDA approval?

Elelyso (taliglucerase alfa for injection), the company's first drug product produced by ProCellEx, was approved for marketing by the FDA in May 2012.

What was a significant financial event for Protalix BioTherapeutics in September 2024?

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes.

When did Protalix BioTherapeutics regain compliance with NYSE American listing standards?

In September 2020, Protalix BioTherapeutics regained compliance with NYSE American continued listing standards.